CPHI: ערך בספרים למניה China Pharma

China Pharma Holdings' leadership in the affordable generics segment in the PRC ensures a stable base income, which, through the book value assessment on the GURU.Markets chart, leads to moderate growth, where the current value is 0.89. However, trade conflicts with the US limit the export of components, forcing the company to rely exclusively on domestic demand.

Environmental footprint control and wastewater neutralization costs at China Pharma Holdings (CPHI) impact the company's net asset structure. By analyzing the book value per share, an investor can see the remaining equity after deducting all liabilities, which allows for an assessment of the real value of the ownership stake and the protection of investments against dilution or asset impairment.